State of New Hampshire
Department of Safety

Division of Fire Standards and Training & Emergency Medical Services
Richard M. Flynn Fire Academy
98 Smokey Bear Boulevard, Concord, New Hampshire
Mailing Address: 33 Hazen Drive, Concord, New Hampshire 03305-0002

John J. Barthelmes
Commissioner

Robert Quinn and Richard C. Bailey, Jr.
Assistant Commissioners

Deborah A. Pendergast
Director

CLINICAL BULLETIN

Bulletin #	Title			Date Issued
46	Naloxone Recall			June 5, 2018
Superseded	**Released By**	**Approved By**	**Source**	
	Vicki Blanchard, NRP	Joey Scollan, DO	FDA & Hospira	

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection. USP in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira, Inc., a Pfizer company, is voluntarily recalling lots **72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/ml, 1 ml in 2.5 ml, Carpuject Single use cartridge syringe system (NOC 0409-1782-69),** to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

In the event that impacted product is administered to a patient, the patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity. The risk is reduced by the possibility of detection, as the labeling contains a clear statement directing visual inspection of the product for particulate matter and discoloration prior to administration. To date, Hospira, Inc. has not received reports of any adverse events associated with this issue for these lots.